Could CAR t cells unlock transplants for 'Impossible to Match' kidney patients?

NCT ID NCT06056102

Recruiting now Disease control Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a new type of immunotherapy called CAR T cells can safely lower the immune system's reactivity in people waiting for a kidney transplant. Participants have a very high chance of rejecting most donor kidneys (cPRA of 99.5% or higher). The treatment involves giving two types of CAR T cells along with chemotherapy to try to reduce this immune barrier. The main goal is to check safety and find the right dose, with a secondary hope of making more kidneys available for transplant.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CAR T cells (CART-BCMA and huCART19) plus chemotherapy (cyclophosphamide)
What this could lead to: If it works, this could help people with very high immune reactivity receive a kidney transplant they would otherwise be rejected for.
What could go wrong: This is a very early, small Phase 1 trial focused on safety, so it may not work as hoped. CAR T therapy can cause serious side effects like cytokine release syndrome and neurotoxicity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END STAGE RENAL FAILURE ON DIALYSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

end stage renal failure kidney failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

END STAGE RENAL FAILURE ON DIALYSIS KIDNEY FAILURE KIDNEY TRANSPLANT

Contacts and locations

Locations

Massachusetts General Hospital: Transplantation (Site #: 71107)
RECRUITING

Boston, Massachusetts, 02114, United States
NYU Langone Health (Site #: 71177)
RECRUITING

New York, New York, 10016, United States
University of Pennsylvania Medical Center (Site #: 71111)
RECRUITING

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.